JP Morgan Maintains Overweight on Rhythm Pharmaceuticals, Lowers Price Target to $145
Benzinga Newsdesk 2 weeks ago
Analyst RatingsNewsPrice Target
JP Morgan analyst Priyanka Grover maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Overweight and lowers the price target from $146 to $145.
JP Morgan analyst Priyanka Grover maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Overweight and lowers the price target from $146 to $145.